Cargando…

Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?

Therapeutic approaches providing effective medication for Alzheimer’s disease (AD) patients after disease onset are urgently needed. Previous studies in AD mouse models and in humans suggested that physical exercise or changed lifestyle can delay AD-related synaptic and memory dysfunctions when trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leßmann, Volkmar, Kartalou, Georgia-Ioanna, Endres, Thomas, Pawlitzki, Marc, Gottmann, Kurt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2023
Materias:	Neurology and Preclinical Neurological Studies - Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374694/ https://www.ncbi.nlm.nih.gov/pubmed/37014414 http://dx.doi.org/10.1007/s00702-023-02618-5

Ejemplares similares

Anti-Inflammatory Treatment with FTY720 Starting after Onset of Symptoms Reverses Synaptic Deficits in an AD Mouse Model
por: Kartalou, Georgia-Ioanna, et al.
Publicado: (2020)

The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod
por: Patmanathan, Sathya Narayanan, et al.
Publicado: (2015)

New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth
por: Alshaker, Heba, et al.
Publicado: (2017)

The emerging role of FTY720 (Fingolimod) in cancer treatment
por: White, Christopher, et al.
Publicado: (2016)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011)

Characterization of the effects of immunomodulatory drug fingolimod (FTY720) on human T cell receptor signaling pathways
por: Baer, Alan, et al.
Publicado: (2018)

Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
por: Sharma, Sushil, et al.
Publicado: (2011)

The Immunosuppressant FTY720 (Fingolimod) enhances Glycosaminoglycan depletion in articular cartilage
por: Stradner, Martin H, et al.
Publicado: (2011)

FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination
por: Blanc, Caroline A, et al.
Publicado: (2014)

Protective role of fingolimod (FTY720) in rats subjected to subarachnoid hemorrhage
por: Xu, Hao-Liang, et al.
Publicado: (2015)

Fingolimod (FTY720) Stimulates Ca(2+)/Calcineurin Signaling in Fission Yeast
por: Hagihara, Kanako, et al.
Publicado: (2013)

FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity
por: Ahmed, Dilruba, et al.
Publicado: (2015)

The Immunosuppressant Fingolimod (FTY720) for the Treatment of Mechanical Force-Induced Abnormal Scars
por: Aoki, Masayo, et al.
Publicado: (2020)

Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy
por: Enoru, Julius O., et al.
Publicado: (2016)

FTY720-derivatives do not induce FTY720-like lymphopenia
por: Segura-Ulate, Ismael, et al.
Publicado: (2017)

FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons
por: Takasugi, Nobumasa, et al.
Publicado: (2013)

Acute Anterior Uveitis in a Patient Taking Fingolimod (FTY720) for Multiple Sclerosis
por: Mack, Heather Gwen, et al.
Publicado: (2016)

Immunomodulatory drug fingolimod (FTY720) restricts the growth of opportunistic yeast Candida albicans in vitro and in a mouse candidiasis model
por: Najarzadegan, Niloofar, et al.
Publicado: (2022)

Effects of FTY720 (Fingolimod) on Proliferation, Differentiation, and Migration of Brain-Derived Neural Stem Cells
por: Tan, Botao, et al.
Publicado: (2016)

Effect of FTY720 (fingolimod) on graft survival in renal transplant recipients: a systematic review protocol
por: Gholamnezhadjafari, Reza, et al.
Publicado: (2016)

Fingolimod (FTY720) improves postoperative cognitive dysfunction in mice subjected to D-galactose-induced aging
por: Zhang, Jie, et al.
Publicado: (2020)

Fingolimod (FTY720-P) Does Not Stabilize the Blood–Brain Barrier under Inflammatory Conditions in an in Vitro Model
por: Schuhmann, Michael K., et al.
Publicado: (2015)

Modulatory Effects of Fingolimod (FTY720) on the Expression of Sphingolipid Metabolism-Related Genes in an Animal Model of Alzheimer’s Disease
por: Jęśko, Henryk, et al.
Publicado: (2018)

Fingolimod (FTY720) Preserves High Energy Phosphates and Improves Cardiac Function in Heterotopic Heart Transplantation Model
por: Ahmed, Naseer, et al.
Publicado: (2020)

FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment
por: Wang, Zifeng, et al.
Publicado: (2020)

FTY720 attenuates excitotoxicity and neuroinflammation
por: Cipriani, Raffaela, et al.
Publicado: (2015)

Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) Attenuates Myocardial Fibrosis in Post-heterotopic Heart Transplantation
por: Ahmed, Naseer, et al.
Publicado: (2017)

Ameliorative effects of Fingolimod (FTY720) on microglial activation and psychosis-related behavior in short term cuprizone exposed mice
por: Li, Siyao, et al.
Publicado: (2023)

Diagnosis and Management of Fingolimod-Associated Macular Edema
por: Wang, Chunjiang, et al.
Publicado: (2022)

Serotonergic drug repurposing in multiple sclerosis: A new possibility for disease-modifying therapy
por: Melnikov, Mikhail, et al.
Publicado: (2022)

Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation
por: Mazzola, Maria Antonietta, et al.
Publicado: (2015)

Fingolimod (FTY720), a Sphinogosine-1-Phosphate Receptor Agonist, Mitigates Choroidal Endothelial Proangiogenic Properties and Choroidal Neovascularization
por: Sorenson, Christine M., et al.
Publicado: (2022)

Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis
por: Petsas, Nikolaos, et al.
Publicado: (2019)

Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod
por: Fukai, Ryoko, et al.
Publicado: (2019)

The Therapeutic Targets of Fingolimod (FTY720) Are Involved in Pathological Processes in the Frontal Cortex of Alzheimer's Disease Patients: A Network Pharmacology Study
por: Yin, Pengqi, et al.
Publicado: (2021)

Sphingomimetic multiple sclerosis drug FTY720 activates vesicular synaptobrevin and augments neuroendocrine secretion
por: Darios, Frederic D., et al.
Publicado: (2017)

Multiple sclerosis drug FTY-720 toxicity is mediated by the heterotypic fusion of organelles in neuroendocrine cells
por: Gimenez-Molina, Yolanda, et al.
Publicado: (2019)

Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma
por: Saeed, Mohamed E. M., et al.
Publicado: (2020)

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration
por: Sehr, Tony, et al.
Publicado: (2020)

Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension
por: Kira, Jun-ichi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_icebcqugoia6skqafit5oi4pq6